These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19091041)

  • 21. Qinghaosu (artemisinin): the price of success.
    White NJ
    Science; 2008 Apr; 320(5874):330-4. PubMed ID: 18420924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.
    Pongtavornpinyo W; Yeung S; Hastings IM; Dondorp AM; Day NP; White NJ
    Malar J; 2008 Nov; 7():229. PubMed ID: 18976503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Awareness of antimalarial policy and use of artemisinin-based combination therapy for malaria treatment in communities of two selected local government areas of Ogun State, Nigeria.
    Adeneye AK; Jegede AS; Mafe MA; Nwokocha EE
    World Health Popul; 2014; 15(1):45-60. PubMed ID: 24702765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimalarial drugs available in the city Cabinda (Angola) in 2016.
    Muila M; Gazin P
    Bull Soc Pathol Exot; 2017 Oct; 110(4):260-264. PubMed ID: 28887771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug development: Holding out for reinforcements.
    Eisenstein M
    Nature; 2012 Apr; 484(7395):S16-8. PubMed ID: 22534526
    [No Abstract]   [Full Text] [Related]  

  • 26. Transitioning from malaria control to elimination: the vital role of ACTs.
    Grueninger H; Hamed K
    Trends Parasitol; 2013 Feb; 29(2):60-4. PubMed ID: 23228225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets.
    Ding XC; Beck HP; Raso G
    Trends Parasitol; 2011 Feb; 27(2):73-81. PubMed ID: 21169061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Artemisinin combination therapies price disparity between government and private health sectors and its implication on antimalarial drug consumption pattern in Morogoro Urban District, Tanzania.
    Malisa AL; Kiriba D
    BMC Res Notes; 2012 Mar; 5():165. PubMed ID: 22455367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness study of three antimalarial drug combinations in Tanzania.
    Wiseman V; Kim M; Mutabingwa TK; Whitty CJ
    PLoS Med; 2006 Oct; 3(10):e373. PubMed ID: 17032059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of pediatric malaria in Africa: act at issue].
    Faucher JF; Missinou MA; Brasseur P
    Med Trop (Mars); 2006 Jun; 66(3):292-4. PubMed ID: 16924825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Affordable medicines facility for malaria.
    Bate R; Hess K
    Lancet Infect Dis; 2009 Jul; 9(7):396-7. PubMed ID: 19555897
    [No Abstract]   [Full Text] [Related]  

  • 32. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
    de Haan F; Bolarinwa OA; Guissou R; Tou F; Tindana P; Boon WPC; Moors EHM; Cheah PY; Dhorda M; Dondorp AM; Ouedraogo JB; Mokuolu OA; Amaratunga C
    PLoS One; 2021; 16(8):e0256567. PubMed ID: 34464398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Control of malaria: market for artemisinin and its derivatives].
    Pilloy J
    Med Trop (Mars); 2006 Dec; 66(6):554-7. PubMed ID: 17286020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights following change in drug policy: a descriptive study for antimalarial prescription practices in children of public sector health facilities in Jharkhand state of India.
    Mishra N; Gupta R; Singh S; Rana R; Shahi B; Das MK; Anvikar AR; Valecha N
    J Vector Borne Dis; 2013 Dec; 50(4):271-7. PubMed ID: 24499849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress toward elimination of malaria in Nigeria: uptake of artemisinin-based combination therapies for the treatment of malaria in households in Benin City.
    Akoria OA; Arhuidese IJ
    Ann Afr Med; 2014; 13(3):104-13. PubMed ID: 24923369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacovigilance of antimalarial treatment in Africa: is it possible?
    Talisuna AO; Staedke SG; D'Alessandro U
    Malar J; 2006 Jun; 5():50. PubMed ID: 16780575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New funding mechanism is launched to combat malaria.
    Moszynski P
    BMJ; 2009 Apr; 338():b1627. PubMed ID: 19380401
    [No Abstract]   [Full Text] [Related]  

  • 38. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance.
    Hastings I
    Trends Parasitol; 2011 Feb; 27(2):67-72. PubMed ID: 20971040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa.
    Snow RW; Eckert E; Teklehaimanot A
    Trends Parasitol; 2003 Aug; 19(8):363-9. PubMed ID: 12901938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing national treatment policy for falciparum malaria in Africa: Malawi experience.
    Malenga G; Wirima J; Kazembe P; Nyasulu Y; Mbvundula M; Nyirenda C; Sungani F; Campbell C; Molyneux M; Bronzan R; Dodoli W; Ali D; Kabuluzi S
    Trans R Soc Trop Med Hyg; 2009 Apr; 103 Suppl 1():S15-8. PubMed ID: 19285699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.